(EMAILWIRE.COM, January 11, 2019 ) The global sinus dilation devices market is expected to reach USD 2.78 billion by 2023 from USD 1.80 billion in 2018, at a CAGR of 9.1%. The growth of this market is mainly driven by the high prevalence of chronic sinusitis, growing preference for minimally invasive procedures, benefits of balloon sinuplasty/sinus dilation over conventional sinus surgeries, and favorable reimbursement scenario for sinus procedures in developed countries.

Agreements, collaborations, partnerships, and expansions are some of the major growth strategies followed by key players between 2015 and 2018. Key players in the sinus dilation devices market include Entellus Medical Inc. (Subsidiary of Stryker) (US), Acclarent Inc. (Subsidiary of Johnson & Johnson) (US), Medtronic plc (Ireland), Smith & Nephew plc (UK), Intersect ENT Inc. (US), and Olympus Corporation (Japan). Other players in the market include Meril Life Sciences Pvt Ltd. (India), SinuSys Corporation (US), InAccel (India), Jilin Coronado Medical Ltd. (China), and Creganna Medical (Ireland).

Download Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=64349810

In 2017, Acclarent (US) was the leading player in the global sinus dilation devices market. The company’s leading position is attributed to its wide presence in key markets such as the US, Europe, APAC, and the Middle East. The company has a vast customer base spanning more than 160 countries and operates in over 370 locations across the globe. The company has a vast product portfolio and specializes in minimally invasive ENT surgery products. It offers a broad range of devices such as balloon sinuplasty systems, ethmoid punch, and airway dilation systems. To maintain its position in the market, Acclarent spends exhaustively on research and development. In 2016, the company spent 12.7% of its revenue (USD 9.10 billion), which was increased to 13.7% of its revenue (USD 10.5 Billion) in 2017.

Major Market Developments

In December 2017, Intersect ENT received FDA approval for the SINUVA (mometasone furoate) Sinus Implant
In December 2017, Stryker completed the acquisition of Entellus (US), a pioneer in providing minimally invasive technologies that enable procedures to be performed in more cost-effective sites of service in the space of sinus dilation.
In June 2016, Entellus had an agreement with Fiagon NA Corporation (US), according to the new expanded agreement, Entellus became the exclusive distributor of Fiagon branded Navigation Systems and accessories in the US and Canada. It enabled Entellus to be the exclusive distributor of Fiagon’s IGS to hospitals, in addition to ear, nose, and throat (ENT) offices and ambulatory surgery centers

Target Audience:

Sinus dilation device manufacturers
Suppliers and distributors of sinus dilation devices
Hospitals, diagnostic centers, and medical colleges
Independent surgeons and private offices of physicians
Ambulatory surgery centers
Teaching hospitals and academic medical centers
Government bodies/municipal corporations
Business research and consulting service providers
Venture capitalists

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
newsletter@marketsandmarkets.com